Brief: Oncternal Therapeutics Initiates Global Registrational Phase 3 Study Of Zilovertamab For Patients With MCL
27/09/2022 14:25
Sept 27 (Reuters) - Oncternal Therapeutics Inc ONCT.O :
* ONCTERNAL THERAPEUTICS INITIATES GLOBAL REGISTRATIONAL
PHASE 3
STUDY OF ZILOVERTAMAB FOR PATIENTS WITH MCL
Source text for Eikon: ID:nGNX2Z2y0N
Further company coverage: ONCT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncternal Therapeutics
See all newsOncternal Therapeutics Inc expected to post a loss of $3.19 a share - Earnings Preview
Brief: Oncternal Therapeutics Workforce Reduction Of About 10 Employees
U.S. STOCKS ON THE MOVE-Unity Software, Viking Holdings, Adobe
U.S. STOCKS ON THE MOVE-Gold miners, silver miners, Warner Bros Discovery
Oncternal hits record low on plans to scrap studies, explore strategic alternatives;